1	Parer	tal genetically predicted liability for coronary heart disease and risk of
2	adver	se pregnancy outcomes
3		
4	Álvaro	o Hernáez ^{1,2,*} , Karoline H. Skåra ^{3,1} , Christian M. Page ^{1,4} , Vera R. Mitter ⁵ , Marta
5	H. He	rnández ^{1,2} , Per Magnus ¹ , Pål R. Njølstad ^{6,7} , Ole A. Andreassen ^{8,9} , Elizabeth C.
6	Corfie	ld ^{10,11} , Alexandra Havdahl ^{10,11,12,13} , Øyvind Næss ^{14,15} , Ben Brumpton ^{16,17,18} ,
7	Bjørn	Olav Åsvold ^{16,17,19} , Deborah A. Lawlor ^{13,20} , Abigail Fraser ^{13,20,†} , Maria Christine
8	Magn	us ^{1,†}
9		
10	1.	Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo,
11		Norway
12	2.	Blanquerna School of Health Sciences, Universitat Ramon Llull, Barcelona,
13		Spain
14	3.	Department of Community Medicine and Global Health, Institute of Health and
15		Society, University of Oslo, Oslo, Norway
16	4.	Department of Physical Health and Ageing, Division for Mental and Physical
17		Health, Norwegian Institute of Public Health, Oslo, Norway
18	5.	Pharmacoepidemiology and Drug Safety Research Group, Department of
19		Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of
20		Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
21	6.	Center for Diabetes Research, Department of Clinical Science, University of
22		Bergen, Bergen, Norway
23	7.	Children and Youth Clinic, Haukeland University Hospital, Bergen, Norway
24	8.	Norwegian Centre for Mental Disorders Research, NORMENT, Division of
25	NOTE: T	Mental Health and Addiction, Oslo University Hospital, Oslo, Norway This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

		1

26	9. Institute of Clinical Medicine, University of Oslo, Oslo, Norway
27	10. Center for Genetic Epidemiology and Mental Health, Norwegian Institute of
28	Public Health, Oslo, Norway
29	11. Nic Waals Institute, Lovisenberg Diakonale Hospital, Oslo, Norway
30	12. PROMENTA Research Center, Department of Psychology, University of Oslo,
31	Oslo, Norway
32	13. Population Health Sciences, Bristol Medical School, University of Bristol,
33	Bristol, UK
34	14. Institute of Health and Society, University of Oslo, Oslo, Norway
35	15. Division of Mental and Physical Health, Norwegian Institute of Public Health,
36	Oslo, Norway
37	16.K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health
38	and Nursing, Norwegian University of Science and Technology, Trondheim,
39	Norway
40	17. HUNT Research Centre, Department of Public Health and Nursing, Norwegian
41	University of Science and Technology, Levanger, Norway
42	18. Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital,
43	Trondheim, Norway
44	19. Department of Endocrinology, Clinic of Medicine, St. Olavs Hospital,
45	Trondheim University Hospital, Trondheim, Norway
46	20. MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK
47	
48	†: both authors contributed equally to this work
49	
50	

51 Corresponding author

- 52 Alvaro Hernaez, PharmD, PhD
- 53 Centre for Fertility and Health, Norwegian Institute of Public Health
- 54 PO 222 Skøyen, 0213 Oslo, Norway
- 55 Telephone: (+47) 95523951
- 56 e-mail: <u>alvaro.hernaez@fhi.no</u>
- 57 ORCID: 0000-0001-8593-1477

58 ABSTRACT

59

Background. Adverse pregnancy outcomes (APO) may unmask a woman's
underlying risk for coronary heart disease (CHD). To test this, we estimated
associations between genetically predicted liability for CHD and risk of APOs in
mothers and their male partners. We hypothesized that associations would be found
for women, but not their partners (negative controls).
Methods. We studied up to 83,969 women (and up to 55,568 male partners)
participating in the Norwegian Mother, Father and Child Cohort Study or the

67 Trøndelag Health Study with genotyping data and information on history of any APO

in their pregnancies (miscarriage, stillbirth, hypertensive disorders of pregnancy,

69 gestational diabetes, small for gestational age, large for gestational age, and

50 spontaneous preterm birth). Maternal and paternal genetic risk scores (GRS) for

71 CHD were generated using 148 gene variants (*p*-value $< 5 \times 10^{-8}$, not in linkage

72 disequilibrium). Associations between GRS for CHD and each APO were determined

using logistic regression, adjusting for genomic principal components, in each cohort

separately, and combined using fixed effects meta-analysis.

75 **Results.** One standard deviation increase in the GRS for CHD in women was related

to increased risk of any hypertensive disorders of pregnancy (odds ratio [OR] 1.08,

77 95% confidence interval [CI] 1.05-1.10), pre-eclampsia (OR 1.08, 95% CI 1.05-1.11),

and small for gestational age (OR 1.04, 95% CI 1.01-1.06). Imprecise associations

with lower odds of large for gestational age (OR 0.98, 95% CI 0.96 to 1.00) and

higher odds of stillbirth (OR 1.04, 95% CI 0.98 to 1.11) were suggested. These

81 findings remained consistent after adjusting for number of total pregnancies and the

82 male partners' GRS and restricting analyses to stable couples. Associations for

5

- 83 miscarriage, gestational diabetes, and spontaneous preterm birth were close to the 84 null. In male partners, there was weak evidence of an association with spontaneous 85 preterm birth (OR 1.02 [0.99 to 1.05]), but not with other APOs. **Conclusions.** Hypertensive disorders of pregnancy, small for gestational age and 86 87 stillbirth unmask women with a genetically predicted existing propensity for CHD. The association of paternal genetically predicted CHD risk with spontaneous preterm birth 88 needs further exploration. 89
- 90

Keywords 91

- 92 Coronary heart disease; adverse pregnancy outcomes; parental genetic liability to
- 93 CHD; MoBa; HUNT
- 94

95 List of abbreviations

- APO: adverse pregnancy outcome 96
- 97 CHD: coronary heart disease
- CI: confidence interval 98
- 99 GD: gestational diabetes
- 100 GRS: genetic risk score
- 101 GWAS: genome-wide association study
- 102 HDP: hypertensive disorders of pregnancy
- 103 HUNT: Trøndelag Health Study
- 104 LGA: large for gestational age
- 105 MBRN: Medical Birth Registry of Norway
- MoBa: Mother, Father, and Child Cohort Study 106
- OR: odds ratio 107

- 108 SGA: small for gestational age
- 109 SD: standard deviation
- 110 sPTB: spontaneous preterm birth

7

111 INTRODUCTION

Adverse pregnancy outcomes (APO), such as miscarriage, stillbirth, hypertensive 113 114 disorders of pregnancy (HDP), gestational diabetes (GD), small for gestational age 115 (SGA), large for gestational age (LGA), and spontaneous preterm birth (sPTB), are 116 thought to unmask a woman's underlying liability for cardiovascular disease. 117 identifying women who 'fail' the cardiometabolic stress test of pregnancy [1]. 118 Preconception cardiovascular risk factors are associated with APOs [2-7] and the 119 extent of physiological changes of pregnancy including vasodilation, decreases in 120 glucose, and changes in lipoprotein subclasses and biomarkers of low-grade 121 inflammation [8]. Moreover, adjustment for preconception cardiovascular risk factors 122 attenuates the relationship between APOs and maternal post-partum risk of 123 cardiovascular disease [9-11]. An association between genetically predicted liability 124 for cardiovascular disease and APOs in women would offer further support to the 125 'unmasking' hypothesis as germline variants are inherited at birth. We therefore investigated associations between maternal and paternal genetic 126 127 liability for coronary heart disease (CHD) with APOs (miscarriage, stillbirth, HDP, GD, 128 SGA, LGA and sPTB). We hypothesized that we would find an association in women 129 but not in men, as men's genetic predisposition to CHD would not be revealed when their female partner undergoes the cardiometabolic stress test of pregnancy. Hence, 130 131 we considered men as imperfect negative controls. Imperfect, because shared family 132 environment associated with both genetic liability for CHD and APO risk (e.g., body 133 mass index, smoking) [12] may result in associations between genetic liability for CHD and APO risk in men. Paternal genetic variants linked to CHD might also impact 134 135 the epigenetics of their reproductive cells or the quality of their sperm quality, and

- 8
- these factors may in turn influence APO risk [13, 14]. Finally, fetal genetics inherited
- 137 from both parents may also affect risk of APOs [15, 16]. We used genetically
- 138 predicted CHD risk as the exposure because CHD is the most common
- 139 cardiovascular disease, the leading cause of death globally, and the cardiovascular
- 140 event with the highest proportion of genetic variance explained in genome-wide
- 141 association studies (GWAS) [17].

142 **METHODS**

143

144 Population description


145 We studied participants in the Norwegian Mother, Father, and Child Cohort Study 146 (MoBa) [18] and the Trøndelag Health Study (HUNT) [19]. MoBa is a pregnancy 147 cohort study led by the Norwegian Institute of Public Health in which pregnant women 148 and their partners were recruited at approximately 17 gestational weeks between 1999 and 2008 all over Norway. The participation rate was 41%, and the cohort 149 150 includes approximately 95,200 women and 75,200 of their male partners [18]. The 151 HUNT study is a population-based cohort of the Trøndelag County in Norway 152 (representative of the general adult Norwegian population regarding morbidity, 153 mortality, income, and age), led by the Norwegian University of Science and 154 Technology and based on four data collection surveys between 1984 and 2019 [19, 155 20]. Both MoBa and HUNT participants are of predominantly European ancestry. 156 Information from the Medical Birth Registry of Norway (MBRN) for participants in both cohorts was obtained by linkage using unique identification numbers. 157 158 This work is based on a subsample of participants in the two cohorts who had

159 at least one registered singleton pregnancy in the MBRN, available genotype data, 160 and information on the pregnancy outcomes of interest (**Figure 1**). Regarding HUNT, 161 as the MBRN has information on all births in Norway from 1967 onwards [21], we 162 restricted our analyses to cohort participants who were 15 years or younger at the 163 time when the MBRN was set up (born 1952 or later), to capture all of their births. 164 Genotype data in both cohorts came from biological samples obtained from 165 participants after genotype calling, imputation, and quality control [20, 22]. This work

10

166 is presented according to the Strengthening the Reporting of Observational Studies

167 in Epidemiology guidelines.



168 **Figure 1**. Flow chart

169

170 Genetic liability for coronary heart disease

171 We obtained publicly available summary data on the genetic variants linked to CHD from the latest GWAS including ~550,000 individuals from the UK Biobank and 172 173 CARDIoGRAMplusC4D cohorts [17]. No MoBa or HUNT participants took part in this 174 GWAS. It identified 148 genetic variants (single nuclear polymorphisms) associated with CHD at genome-wide significance (*p*-value $< 5 \times 10^{-8}$) and independent of each 175 other (i.e., not in linkage disequilibrium [pairwise $r^2 < 0.1$ and a physical distance of at 176 177 least 5,000bps]) [23]. 141 and 146 of these genetic variants were available in the MoBa and HUNT databases, respectively. We used these variants to calculate 178 179 weighted genetic risk scores (GRSs) for CHD, representing the genetic liability for CHD [24]. The exact genetic variants used in each cohort is available in 180 Supplemental Table 1. 181

11

183 Adverse pregnancy outcomes

184 APOs were defined using information from the MBRN for both cohorts. We identified 185 individuals in MoBa and HUNT with any history of any APO across all their registered 186 pregnancies from 1967 to 2019. Miscarriage was defined as any fetal loss prior to 23 187 completed gestational weeks, while stillbirth was defined as any fetal death after 23 188 completed gestational weeks, as registered in the MBRN [21]. The MBRN contains 189 self-reported information on the number of prior miscarriages and stillbirths at the 190 time of each registered pregnancy (it is not possible to distinguish the exact 191 gestational age of prior pregnancies not registered in the MBRN), in addition to the 192 status and gestational age of the registered pregnancies. We combined the self-193 reported information on previous pregnancies and the registered pregnancies to 194 define complete history of miscarriage and stillbirth. HDP was defined as having any 195 registration of gestational hypertension, preeclampsia, eclampsia, or Hemolysis, Elevated Liver enzymes and Low Platelets syndrome in the absence of hypertension 196 197 prior to the pregnancy [25]. Registrations of GD in the MBRN are made according to the criteria of the Norwegian Society of Gynecology and Obstetrics in the absence of 198 199 a history of diabetes [26]. Notably, there is no information on blood pressure 200 measurements, proteinuria levels or glucose levels in the MBRN. The registrations of 201 HDP and GD are therefore made based on the national clinical guidelines at the time 202 [25, 26]. Gestational age was estimated using ultrasound around 18 completed 203 gestational week or last menstrual period for the small proportion without an 204 ultrasound assessment. SGA was defined as birth weight <10th percentile for 205 gestational age and biological sex [27], whilst LGA was defined as birth weight ≥90th percentile for gestational age and biological sex of the offspring. Participants who 206 207 delivered an SGA baby were excluded from the analyses on LGA and vice versa.

12

208	Any non-medically induced delivery prior to the 37 th week of pregnancy was
209	considered a sPTB (induced deliveries and C-sections were excluded from the
210	reference group) [28].
211	

211

212 Descriptive variables

213 To describe the characteristics of our population, we obtained information on birth 214 year (value in the first pregnancy in MBRN, continuous), the number of pregnancies 215 in which the participants were involved (continuous), whether the study participants 216 were involved in pregnancies with more than one partner (yes/no), years of education 217 (value registered in the first MoBa/HUNT guestionnaire available, continuous), body 218 mass index (value registered in the first MoBa/HUNT questionnaire available, in 219 kg/m²), having ever smoked (yes/no), and highest obtained parity (stillbirths plus live 220 births according to the MBRN, continuous) [29, 30].

221

222 Ethical approval and consent to participate

223 Both MoBa and HUNT follow the Declaration of Helsinki for Medical Research on 224 human subjects. MoBa is currently regulated by the Norwegian Health Registry Act 225 and its data collection is approved by the Norwegian Data Protection Authority. 226 HUNT was authorized by the Regional Committee for Medical and Health Research 227 (Health Region IV, Norway). Participants provided a written informed consent before 228 joining the cohorts. This project was particularly approved by the Regional Committee for Medical and Health Research Ethics of South/East Norway (references: 229 230 2017/1362 and 78545).

231

232 Statistical analyses

13

We describe the distributions of normally distributed continuous variables using means and standard deviations (SDs), non-normally distributed continuous variables using medians and 1st-3rd quartiles, and categorical variables using numbers and percentages. We assessed differences between participants with and without genotype information using t-tests (normally distributed continuous variables), Mann-Whitney U-tests (non-normally distributed continuous variables), and chi-squared tests (categorical variables).

We studied the association between a one SD higher GRS for CHD and risk of 240 241 APOs, in mothers and their male partners separately, using logistic regression. We 242 analyzed MoBa and HUNT data individually, and subsequently meta-analyzed their 243 estimates using a fixed effects model, assuming participants from both cohorts come 244 from the same underlying population and any difference in associations is random. 245 We tested this assumption using the Cochrane Q-test for between-study 246 heterogeneity, using a p-value threshold of <0.1 as an indication of heterogeneity 247 given the statistical inefficiency of between-study heterogeneity tests and the smaller sample size of HUNT compared to MoBa. If significant heterogeneity was detected 248 249 for any of the outcomes, we meta-analyzed the estimates of the two studies using a 250 random effects model as a complementary analysis. We reduced confounding of the 251 relationship between GRSs for CHD and the outcomes due to population stratification 252 by adjusting our analyses for the first 20 ancestry-informative principal components 253 [31]. Analyses were further adjusted for genotype batch.

As parental negative control analyses (i.e., comparing maternal associations to paternal associations) can be biased by assortative mating and other shared if they are not mutually adjusted for each other [32], we repeated our main analyses in the subgroup of mothers and their partners where both had genetic data. We present

14

results in this subgroup without and with mutual adjustment. The former analysis,
when compared with the main results, explores evidence of selection bias in the
subsample in couples with genetic data.

261 We conducted additional sensitivity analyses. Firstly, the more pregnancies a person has, the higher the likelihood of detecting an effect of parental genetic 262 263 predisposition to CHD on the risk of APO. To minimize this bias, we further adjusted 264 for the total number of pregnancies the participant had. Secondly, a participant who had pregnancies with various partners might have a differing risk of APO with each 265 partner. Therefore, we performed another sensitivity analysis that was confined to 266 267 stable couples only (i.e., participants without pregnancies with different partners 268 according to the MBRN). 269

270 <u>Software</u>

271 We conducted our analyses in R Software v. 4.0.3. Our analysis code is available in

- 272 <u>https://github.com/alvarohernaez/</u>
- 273 <u>GRS_CHD_pregnancy_complications_MoBa_HUNT/</u>.

274 **RESULTS**

- 275
- 276 Study population
- 277 Our analyses were conducted in up to 68,882 women and 47,474 of their male
- partners in MoBa, and up to 15,087 women and 8,094 of their male partners in HUNT
- 279 (Figure 1), described in Table 1. Meta-analyses of the main analyses involved
- between 66,110 (SGA) and 83,900 women (stillbirth and GD) and between 43,967
- (SGA) and 55,790 men (stillbirth and GD). The exact sample sizes for all analyses
- are available in **Supplementary Table 2**.
- 283

284 **Table 1.** Population description

	MoBa		HUNT	
	Women	Male partners	Women	Male partners
	(<i>n</i> = 68,882)	(<i>n</i> = 47,474)	(<i>n</i> = 15,087)	(<i>n</i> = 8,094)
Birth year, range	1954-1993	1938-1990	1952-1988	1952-1988
Number of pregnancies,	2 (2-3)	2 (2-3)	2 (2-3)	2 (2-3)
median (1 st -3 rd quartile; range)	[range: 1-14]	[range: 1-14]	[range: 1-10]	[range: 1-10]
Participants in pregnancies				
with more than one different	9,147	5,819	745	178
partner, <i>n</i> (%)	(13.3%)	(12.3%)	(4.74%)	(2.08%)
Age in first pregnancy, median	27	29	24	26
(1 st -3 rd quartile)	(24-30)	(26-33)	(20-27)	(23-29)
Education years,				
mean ± SD	17.0 ± 3.36	16.3 ± 3.56	14.3 ± 4.13	13.5 ± 4.08
Body mass index (kg/m ²),	23.1	25.4	25.2	26.6

median (1 st -3 rd quartile)	(21.1-25.9)	(23.6-27.7)	(22.7-28.6)	(24.5-29.1)
Ever smokers, <i>n</i> (%)	35,631	24,294	8,865	4,233
	(52.3%)	(51.2%)	(57.0%)	(50.1%)
Total number of deliveries:				
0, <i>n</i> (%)	0	0	1,598	595
	(0%)	(0%)	(10.5%)	(7.00%)
1, <i>n</i> (%)	4,611	2,894	6,849	4,041
	(6.71%)	(6.12%)	(45.1%)	(47.5%)
2, <i>n</i> (%)	32,186	23,368	5,088	3,056
	(46.8%)	(49.4%)	(33.5%)	(36.0%)
3, <i>n</i> (%)	24,121	16,357	1,285	654
	(35.1%)	(34.6%)	(8.46%)	(7.69%)
4 or more, <i>n</i> (%)	7,784	4,671	378	154
	(11.3%)	(9.88%)	(2.49%)	(1.81%)
Miscarriage,	20,866	14,451	1,950	1,145
n (%)	(30.4%)	(30.6%)	(30.0%) ^a	(29.6%) ^a
Stillbirth,	872	581	198	84
n (%)	(1.27%)	(1.23%)	(1.30%)	(0.99%)
Hypertensive disorders of	7,288	5,186	1,500	870
pregnancy, <i>n</i> (%)	(10.6%)	(11.0%)	(9.87%)	(10.2%)
Pre-eclampsia + eclampsia, n	5,143	3,589	1,080	641
(%)	(7.49%)	(7.59%)	(7.11%)	(7.54%)
Gestational diabetes,	1,495	1,041	127	62
n (%)	(2.18%)	(2.20%)	(0.84%)	(0.73%)

17

Small for gestational age,	10,552	7,354	1,544	862
n (%)	(15.8%)	(16.0%)	(10.2%)	(10.1%)
Large for gestational age,	14,620	9,880	1,733	1,070
n (%)	(21.7%)	(21.3%)	(11.4%)	(12.6%)
Spontaneous preterm birth,	6,282	4,187	2,643	1,509
n (%)	(9.18%)	(8.89%)	(17.5%)	(17.8%)

285 ^a: analyses restricted to 1998 or later pregnancies.

286

MoBa participants with genotype information were not meaningfully different in 287 their birth year, total number of pregnancies, proportion of stable couples, age at first 288 289 pregnancy, years of education, body mass index, smoking, or number of deliveries in 290 relation to those without genotype data. However, they were slightly less likely to 291 have experienced stillbirth, GD, SGA, and sPTB (Supplementary Table 3). HUNT 292 participants with genotype data were born on average 12 years earlier but were not 293 meaningfully different on their total number of pregnancies, proportion of stable couples, age at first birth, years of education, body mass index, and smoking. 294 295 However, they were more like to experience several APOs (stillbirth, HDP, SGA, 296 LGA, and sPTB) and less likely to have a history of GD (Supplemental Table 3). 297 298 Genetically predicted CHD and adverse pregnancy outcomes

299 Figure 2 shows the main analyses and all additional and sensitivity analyses for 300 women (Panel A) and men (Panel B).

In women, a one SD higher GRS for CHD was associated with 8% greater 301 302 odds of HDP (OR 1.08, 95% CI 1.05 to 1.10), 8% greater odds of preeclampsia (OR 303 1.08, 95% CI 1.05 to 1.11), and 4% greater odds of having an SGA baby (OR 1.04,

18

304 95% CI 1.01 to 1.06). There was evidence of an inverse association between the 305 GRS for CHD and LGA (+1 SD in GRS: OR 0.98, 95% CI 0.96 to 1.00). A positive but 306 imprecise relationship was found for stillbirth (OR 1.04, 95% CI 0.98 to 1.11) and no 307 association was found with sPTB. These findings remained consistent in the subset 308 with genetic data on both parents when adjusting for partners' GRS, as well as in sensitivity analyses adjusting for the number of total pregnancies and restricting the 309 310 analyses to stable couples. Stronger associations between the GRS for CHD and the 311 risk of miscarriage and GD were observed in couples with genotype information in 312 both parents.

In male partners, no association between the GRS for CHD and any APO was
observed, except for evidence of a relationship between the GRS for CHD and
greater odds of sPTB (OR 1.02, 95% CI 0.99 to 1.05). Estimates remained robust in
all sensitivity analyses.


317 Between-study heterogeneity was detected for two outcomes: the association of the GRS for CHD with GD in women (MoBa: OR 1.04, 95% CI 0.99 to 1.09; HUNT: 318 OR 0.86, 95% CI 0.72 to 1.03; p-value for between-study heterogeneity = 0.045; 319 320 random effects meta-analysis: OR 0.96, 95% CI 0.30 to 3.09), and with sPTB in men 321 (MoBa: OR 1.04, 95% CI 1.01 to 1.07; HUNT: OR 0.97, 95% CI 0.92 to 1.03; p-value for between-study heterogeneity = 0.053; random effects meta-analysis: OR 1.01, 322 323 95% CI 0.68 to 1.50). For the rest of the outcomes, findings were consistent between 324 the two cohorts (Supplemental Figure 1).

perpetuity. All rights reserved. No reuse allowed without permission.

19

325 Figure 2. Associations between a one SD higher genetic risk score for coronary

326 heart disease and pregnancy outcomes in women (A) and men (B).



³²⁷ Sample sizes vary from 40,703 to 83,900 in women, and from 39,334 to 55,790 in

male partners, being smallest for the analyses in the subgroup with genetic data on

both parents (see Supplementary Table 2 for information on sample sizes).

20

330 **DISCUSSION**

331

Maternal genetic CHD risk was associated with increased risk of HDP, preeclampsia, and SGA. Weak evidence with confidence intervals spanning the null was found for associations with greater risk of stillbirth and reduced risk of LGA. Null associations with miscarriage, GD, and sPTB were observed. We also found weak evidence of an association between genetic CHD risk with sPTB in men, with associations with other outcomes in men all being close to the null.

338 Our findings support the hypothesis that a woman's existing predisposition to 339 cardiovascular disease may be revealed during pregnancy, specifically through HDP 340 and SGA [1]. The lack of association between male partners' GRS for CHD and these conditions supports these APOs reflecting maternal pre-existing risk of 341 342 cardiovascular disease. This agrees with previous evidence showing that women who developed these APOs had a greater burden of cardiovascular risk factors 343 before pregnancy [5, 6]. Moreover, high levels of genetically determined 344 345 cardiovascular risk factors, such as blood pressure, body mass index, and type-2 346 diabetes, have been linked to a higher likelihood of preeclampsia or eclampsia [33]. Finally, a recent maternal GWAS of preeclampsia and gestational hypertension found 347 348 similar associations between the preeclampsia and gestational hypertension 349 polygenic risk scores and hypertension and related outcomes as those seen in 350 GWASs of men and non-pregnant women, leading authors to conclude that the loci 351 associated with preeclampsia and gestational hypertension were not pregnancy specific, rather that pregnancy unmasks existing risk [34]. 352

In relation to the association between the maternal genetically predicted CHD risk and other APOs, pregnancy loss is a heterogeneous condition, and maternal predisposition to cardiovascular disease may only be relevant to specific subsets of

21

losses. Stillbirth, which was suggestively linked to greater genetic liability for CHD in 356 357 our study, is thought to be induced by placental insufficiency and fetal growth 358 restrictions due to some cardiovascular risk factors during pregnancy, such as hypertension [35-37]. Our findings also revealed an unexpected inverse association 359 360 between the GRS for CHD and LGA. However, given the small magnitude of the relationship in comparison to the other APOs, and the established role of glucose 361 362 metabolic disturbances (such as type 1 diabetes, GD or prediabetic states due to excess weight) in increasing the risk of having LGA babies [38-40], it would be 363 364 advisable to validate the association between the GRS for CHD and LGA in future 365 studies involving other populations. As for GD, it has been shown to be closely 366 related to type 2 diabetes, including with a recent GWAS showing strong genetic 367 correlation between the two [41]. Given the associations of type 2 and GD with 368 cardiovascular disease [42, 43], it is surprising that we did not see an association of 369 the maternal GRS for CHD with GD in our study. Limited cases in our population 370 (~2%), the between-study heterogeneity in MoBa and HUNT for this outcome, changes in diagnostic criteria for GD in Norway (which were large and occurred 371 372 within the time frame of both studies) [26], and underrepresentation in the early years 373 of the MBRN (the precise definition of GD, which differentiates between the diabetic 374 status of the pregnant mother before and during pregnancy, was introduced in the MBRN registration forms in December 1998) [44] may contribute to systematic errors 375 376 in its diagnosis and hinder our ability to find robust associations. Finally, the lack of association between maternal genetically predicted CHD and sPTB may be due to 377 378 the fact that not all risk factors for this condition are cardiovascular-related [45]. 379 We conceptualized paternal genetic CHD risk as an imperfect negative control, as an association between the paternal GRS for CHD and APO risk could not 380

22

arise from a direct stress test of pregnancy but associations might arise from shared 381 382 family environment, paternally transmitted genetic variants of the fetus [46] or a 383 maternal immunological response to pregnancy [47]. The mutual adjustment of paternal for maternal GRS should limit the effect of shared family environment, 384 385 making this an unlikely explanation for the association between the GRS for CHD in male partners and risk of sPTB. There is evidence of both maternal and paternal 386 387 genetic effects on gestational duration [48]. However, this is not consistent with our 388 findings (some evidence of an association in men and no strong evidence of such a 389 relationship in women). Given the number of associations that we have explored, and 390 the different association observed in MoBa and HUNT (affected by between-study 391 heterogeneity), it is possible that the association of paternal GRS for CHD with sPTB 392 is a chance finding, which we would suggest treating with caution unless replicated in 393 other independent studies. Of note, the relationships between the maternal GRS for 394 CHD and HDP, pre-eclampsia, SGA and stillbirth were not attenuated after adjusting 395 for the male partners' GRS for CHD, suggesting that these relationships are specific to women and supporting these APOs likely reflecting pre-existing cardiovascular 396 397 risk.

398 Our study has some limitations. Firstly, male partners were considered as imperfect negative controls in our study, mainly due to the shared family environment 399 that could lead to associations between paternal GRS for CHD and APOs. However, 400 401 the mutual adjustment of maternal and paternal exposures in negative control 402 analyses aims to control for these shared factors, including those occurring by 403 assortative mating [32]. This imperfection may also be due to the fact that paternal genetic variants related to CHD could affect their reproductive cells' epigenetics and 404 405 guality and may impact certain placental characteristics that depend on the fetal

23

genotype, which might subsequently alter the risk of APOs by alternative 406 407 mechanisms [13-16]. Secondly, we identified differences between MoBa and HUNT 408 participants with and without genotype data, which could result in selection bias and 409 reduce our external validity. Differences in MoBa might stem from blood sampling 410 during pregnancy or at delivery and it could be less likely if APOs had been detected. 411 In HUNT, genotyped participants were older. However, selection bias had minimal 412 impact on pregnancy outcomes when comparing MoBa with the general Norwegian 413 population [49]. Thirdly, GD diagnosis may have been affected by systematic errors 414 that may decrease our capacity to find robust associations with this outcome [26, 44]. 415 Fourthly, we could not calculate sex-specific GRSs for CHD exposures due to the 416 lack of sex-specific results in the largest GWAS on CHD. We assumed no sex 417 differences in the GRS for CHD, but if untrue, our findings might be biased. Lastly, 418 our study population's characteristics (predominantly adult European men and women) limit the generalizability of our findings to other populations. Despite these 419 420 limitations, our study has several strengths. To our knowledge, it is the first to 421 investigate the role of genetic liability for CHD in APOs, conducted in a large, well-422 characterized, and genetically homogeneous population. This complements previous 423 studies that have shown associations of cardiovascular risk factors (e.g., high blood 424 pressure, dyslipidemia, impaired glucose tolerance) with APOs [2-7], by using a GRS 425 that captures environmental (i.e., genetic risk of higher body mass, smoking, 426 education, etc.) as well as likely biological risk for CHD. Unlike those previous 427 studies, interpretation of the magnitude of a one SD difference in a genetic risk score 428 for CHD is unclear. For example, the relative 8% increased odds for HDP and pre-429 eclampsia (OR 1.08, for both) appears small but must be understood in the context 430 that the genetic variants that we used in the GRS explain ~15% of the variation in

- CHD risk. We interpret our results as a qualitative indication of the association 431
- between a propensity to CHD influencing the risk of APOs, rather than trying to 432
- 433 quantify that relationship.

434 CONCLUSIONS

- 435
- 436 Our results indicate that pregnancy may unmask a woman's pre-existing
- 437 cardiovascular risk and suggest that a family history of cardiovascular disease or
- 438 early onset of cardiovascular outcomes could help identify individuals who might
- 439 benefit from advice and closer monitoring before and during pregnancy.

440 **DECLARATIONS**

441

- 442 **Consent for publication**
- 443 Not applicable.

444

445 Availability of data and materials

- 446 The consent given by the MoBa and HUNT participants does not allow for storage of
- 447 individual data in repositories or journals. Researchers who want to access MoBa
- datasets for replication should apply by sending an e-mail to <u>datatilgang@fhi.no</u>. This
- 449 procedure requires approval from the Regional Committee for Medical and Health
- 450 Research Ethics in Norway and an agreement with MoBa. Data from the HUNT
- 451 Study used for research are available upon request to the HUNT Data Access
- 452 Committee (<u>hunt@medisin.ntnu.no</u>) to research groups who meet the data
- 453 availability requirements described in <u>http://www.ntnu.edu/hunt/data</u>. Source data of
- the GWAS on CHD are available in the Online Table VI of the article of Van Der
- 455 Harst P et al., Circ Res, 2018, available in the Supplemental Materials
- 456 (https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.117.312086), as well
- 457 as in the IEU Open GWAS website (code: ebi-a-GCST005195).
- 458

459 **Competing interests**

- 460 O.A.A. is a consultant for cortechs.ai and has received speaker's honoraria from
- 461 Sunovion, Janssen, and Lundbeck. D.A.L. receives (or has received in the last 10
- 462 years) research support from National and International government and charitable
- 463 bodies, Roche Diagnostics and Medtronic for research unrelated to the current work.
- 464 The rest of the authors no conflict of interest.

27

465 **Funding**

466 This project received funding from the European Research Council under the 467 European Union's Horizon 2020 research and innovation program (grant agreement number 947684, 964874, and 101021566). This work was also supported by the 468 469 Research Council of Norway through its Centres of Excellence funding scheme, 470 project number 262700, and partly funded by the Research Council of Norway. 471 project "Women's fertility – an essential component of health and well-being" (project 472 number 320656), and project number 223273. Open Access funding was provided by 473 the Norwegian Institute of Public Health. P.R.N. was supported by the European 474 Research Council (grant agreement No 293574). E.C. and A.Havdahl were 475 supported by the Research Council of Norway (274611) and the South-Eastern 476 Norway Regional Health Authority (project numbers 2020022, 2021045). B.B. and 477 B.O.A. work at the K.G. Jebsen Center for Genetic Epidemiology, which is financed by Stiftelsen Kristian Gerhard Jebsen; Faculty of Medicine and Health Sciences, 478 479 NTNU, Norway. D.A.L. and A.F. are affiliated with a unit that receives funding from the UK Medical Research Council (MC UU 00032/05). D.A.L. was supported by the 480 481 British Heart Foundation (CH/F/20/90003 and AA/18/1/34219) and the European 482 Research Council (grant agreement No 101021566). The funders had no role in the collection, analysis, and interpretation of data; in the writing of the report; or in the 483 484 decision to submit the article for publication.

485

486 Author contributions

A.F. and M.C.M. conceived and designed the study, obtained funding, and
coordinated the project. A.Hernaez, and M.C.M. are responsible for the data curation
and the formal analysis. K.H.S. and C.M.P. provided support in data analysis,

\sim	o
2	o

490	software use, and visualization of results. A.Hernaez, K.H.S., C.M.P., V.R.M.,
491	M.H.H., P.M., P.R.N, O.A., E.C., A.Havdahl, Ø.N., B.B., B.O.Å., D.A.L., A.F., and
492	M.C.M. were involved in the definition of the methodology of the study and the
493	interpretation of data. A.Hernaez prepared the first draft of the manuscript, and
494	K.H.S., C.M.P., V.R.M., M.H.H., P.M., P.R.N, O.A., E.C., A.Havdahl, Ø.N., B.B.,
495	B.O.Å., D.A.L., A.F., and M.C.M. revised it critically.

496

497 Acknowledgements

498 The MoBa Cohort Study is supported by the Norwegian Ministry of Health and Care 499 Services and the Ministry of Education and Research. The HUNT Study is a 500 collaboration between HUNT Research Centre (Faculty of Medicine and Health 501 Sciences, Norwegian University of Science and Technology), Trøndelag County 502 Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. The genotyping in HUNT was financed by the National Institutes of 503 504 Health; University of Michigan; the Research Council of Norway; the Liaison Committee for Education, Research and Innovation in Central Norway; and the Joint 505 506 Research Committee between St. Olavs Hospital and the Faculty of Medicine and 507 Health Sciences, NTNU. We are grateful to all the participants in Norway who take 508 part in the MoBa and HUNT studies, those who contributed to the recruitment, and 509 the infrastructure surrounding both cohorts.

510 We thank the Norwegian Institute of Public Health for generating high-quality 511 genomic data in the MoBa study. This research is part of the HARVEST 512 collaboration, supported by the Research Council of Norway (#229624). We also 513 thank the NORMENT Centre for providing genotype data, funded by the Research 514 Council of Norway (#223273), South East Norway Health Authority, and Stiftelsen

515	Kristian Gerhard Jebsen. We further thank the Center for Diabetes Research
516	(University of Bergen) for providing genotype information and performing quality
517	control and imputation of the data, in the context of research projects funded by the
518	European Research Council Advanced Grant SELECTionPREDISPOSED, Stiftelsen
519	Kristian Gerhard Jebsen, the Trond Mohn Foundation, the Research Council of
520	Norway, the Novo Nordisk Foundation, the University of Bergen, and the Western
521	Norway Health Authority.
522	This work was developed on the TSD (Tjeneste for Sensitive Data) online
523	facilities, owned by the University of Oslo, which are operated and developed by the
524	TSD service group at the IT-Department in University of Oslo (<u>tsd-drift@usit.uio.no</u>).
525	This paper does not necessarily reflect the position or policy of the Norwegian
526	Research Council.

527 REFERENCES

529	1.	Sattar N, Greer IA: Pregnancy complications and maternal cardiovascular risk: opportunities
530		for intervention and screening? Bmj 2002, 325(7356):157-160.
531	2.	Egeland GM, Klungsøyr K, Øyen N, Tell GS, Næss Ø, Skjærven R: Preconception
532		Cardiovascular Risk Factor Differences Between Gestational Hypertension and
533		Preeclampsia: Cohort Norway Study. Hypertension 2016, 67(6):1173-1180.
534	3.	Retnakaran R, Shah BR: Divergent Trajectories of Cardiovascular Risk Factors in the Years
535		Before Pregnancy in Women With and Without Gestational Diabetes Mellitus: A
536		Population-Based Study. Diabetes Care 2020, 43(10):2500-2508.
537	4.	Foo FL, Mahendru AA, Masini G, Fraser A, Cacciatore S, MacIntyre DA, McEniery CM,
538		Wilkinson IB, Bennett PR, Lees CC: Association Between Prepregnancy Cardiovascular
539		Function and Subsequent Preeclampsia or Fetal Growth Restriction. Hypertension 2018,
540		72 (2):442-450.
541	5.	Haug EB, Horn J, Markovitz AR, Fraser A, Vatten LJ, Macdonald-Wallis C, Tilling K,
542		Romundstad PR, Rich-Edwards JW, Åsvold BO: Life Course Trajectories of Cardiovascular
543		Risk Factors in Women With and Without Hypertensive Disorders in First Pregnancy: The
544		HUNT Study in Norway. J Am Heart Assoc 2018, 7(15):e009250.
545	6.	Horn J, Haug EB, Markovitz AR, Fraser A, Vatten LJ, Romundstad PR, Rich-Edwards JW, Åsvold
546		BO: Life Course Trajectories of Maternal Cardiovascular Risk Factors according to Offspring
547		Birthweight: The HUNT Study. Sci Rep 2020, 10 (1):10436.
548	7.	Markovitz AR, Haug EB, Horn J, Fraser A, Tilling K, Rimm EB, Missmer SA, Williams PL,
549		Romundstad PR, Åsvold BO et al: Normotensive preterm delivery and maternal
550		cardiovascular risk factor trajectories across the life course: The HUNT Study, Norway. Acta
551		<i>Obstet Gynecol Scand</i> 2021, 100 (3):425-435.
552	8.	Wang Q, Würtz P, Auro K, Mäkinen VP, Kangas AJ, Soininen P, Tiainen M, Tynkkynen T,
553	•	Jokelainen J, Santalahti K <i>et al</i> : Metabolic profiling of pregnancy: cross-sectional and
554		longitudinal evidence. BMC Med 2016, 14 (1):205.
555	9.	Stuart JJ, Tanz LJ, Rimm EB, Spiegelman D, Missmer SA, Mukamal KJ, Rexrode KM, Rich-
556	5.	Edwards JW: Cardiovascular Risk Factors Mediate the Long-Term Maternal Risk Associated
557		With Hypertensive Disorders of Pregnancy. J Am Coll Cardiol 2022, 79 (19):1901-1913.
558	10.	Tobias DK, Stuart JJ, Li S, Chavarro J, Rimm EB, Rich-Edwards J, Hu FB, Manson JE, Zhang C:
559	10.	Association of History of Gestational Diabetes With Long-term Cardiovascular Disease Risk
560		in a Large Prospective Cohort of US Women. JAMA Intern Med 2017, 177 (12):1735-1742.
561	11.	Romundstad PR, Magnussen EB, Smith GD, Vatten LJ: Hypertension in pregnancy and later
562	11.	cardiovascular risk: common antecedents? 2010(1524-4539 (Electronic)).
563	12.	Borges MC, Clayton G, Freathy RM, Felix JF, Fernández-Sanlés A, Gonçalves Soares A, Kilpi F,
564	12.	Yang Q, McEachan RRC, Richmond RC <i>et al</i> : Integrating multiple lines of evidence to assess
565		
		the effects of maternal BMI on pregnancy and perinatal outcomes in up to 497,932 women.
566 567	10	medRxiv 2022:2022.2007.2022.22277930.
567	13.	Galaviz-Hernandez C, Sosa-Macias M, Teran E, Garcia-Ortiz JE, Lazalde-Ramos BP: Paternal
568		Determinants in Preeclampsia. Front Physiol 2018, 9:1870.
569	14.	Sharp GC, Lawlor DA: Paternal impact on the life course development of obesity and type 2
570		diabetes in the offspring. <i>Diabetologia</i> 2019, 62 (10):1802-1810.
571	15.	Beaumont RN, Flatley C, Vaudel M, Wu X, Chen J, Moen G-H, Skotte L, Helgeland Ø, Sole-
572		Navais P, Banasik K et al: Genome-wide association study of placental weight in 179,025
573		children and parents reveals distinct and shared genetic influences between placental and
574		fetal growth. medRxiv 2022:2022.2011.2025.22282723.

575 576 577	16.	Tyrmi JS, Kaartokallio T, Lokki AI, Jääskeläinen T, Kortelainen E, Ruotsalainen S, Karjalainen J, Ripatti S, Kivioja A, Laisk T <i>et al</i> : Genetic Risk Factors Associated With Preeclampsia and Hypertensive Disorders of Pregnancy . <i>JAMA Cardiol</i> 2023.
578 579	17.	van der Harst P, Verweij N: Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease. <i>Circ Res</i> 2018, 122 (3):433-
580 581 582	18.	443. Magnus P, Birke C, Vejrup K, Haugan A, Alsaker E, Daltveit AK, Handal M, Haugen M, Høiseth G, Knudsen GP <i>et al</i> : Cohort Profile Update: The Norwegian Mother and Child Cohort Study
583		(MoBa). Int J Epidemiol 2016, 45 (2):382-388.
584 585 586	19.	Åsvold BO, Langhammer A, Rehn TA, Kjelvik G, Grøntvedt TV, Sørgjerd EP, Fenstad JS, Heggland J, Holmen O, Stuifbergen MC <i>et al</i> : Cohort Profile Update: The HUNT Study, Norway . <i>Int J Epidemiol</i> 2022.
587	20.	Brumpton BM, Graham S, Surakka I, Skogholt AH, Løset M, Fritsche LG, Wolford B, Zhou W,
588	20.	Nielsen JB, Holmen OL <i>et al</i> : The HUNT Study: a population-based cohort for genetic
589		research. medRxiv 2021.
590	21.	Irgens LM: The Medical Birth Registry of Norway. Epidemiological research and surveillance
591		throughout 30 years. Acta Obstet Gynecol Scand 2000, 79(6):435-439.
592	22.	Corfield EC, Frei O, Shadrin AA, Rahman Z, Lin A, Athanasiu L, Akdeniz BC, Hannigan L,
593		Wootton RE, Austerberry C et al: The Norwegian Mother, Father, and Child cohort study
594		(MoBa) genotyping data resource: MoBaPsychGen pipeline v.1. bioRxiv 2022.
595	23.	SNPs for coronary artery disease (Dataset: ebi-a-GCST005195)
596		[https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST005195/]
597	24.	Choi SW, Mak TS, O'Reilly PF: Tutorial: a guide to performing polygenic risk score analyses.
598		Nat Protoc 2020, 15 (9):2759-2772.
599	25.	Scott G, Gillon TE, Pels A, von Dadelszen P, Magee LA: Guidelines-similarities and
600		dissimilarities: a systematic review of international clinical practice guidelines for
601		pregnancy hypertension. Am J Obstet Gynecol 2022, 226(2s):S1222-s1236.
602	26.	Norwegian Guidelines for gestational diabetes (Svangerskapsdiabetes)
603		[https://www.legeforeningen.no/foreningsledd/fagmed/norsk-gynekologisk-
604		forening/veiledere/veileder-i-fodselshjelp/svangerskapsdiabetes/]
605 606	27.	Reforma LG, Febres-Cordero D, Trochtenberg A, Modest AM, Collier AY, Spiel MH: Incidence of small-for-gestational-age infant birthweight following early intertwin fetal growth
607	28.	discordance in dichorionic and monochorionic twin pregnancies. Am J Obstet Gynecol 2021.
608 609	20.	Reddy UM, Deshmukh U, Dude A, Harper L, Osmundson SS: Society for Maternal-Fetal Medicine Consult Series #58: Use of antenatal corticosteroids for individuals at risk for late
610		preterm delivery: Replaces SMFM Statement #4, Implementation of the use of antenatal
611		corticosteroids in the late preterm birth period in women at risk for preterm delivery,
612		August 2016. Am J Obstet Gynecol 2021, 225(5):B36-b42.
613	29.	Skåra KH, Åsvold BO, Hernáez Á, Fraser A, Rich-Edwards JW, Farland LV, Næss Ø, Lawlor DA,
614	201	Brumpton B, Magnus MC: Risk of cardiovascular disease in women and men with
615		subfertility: the Trøndelag Health Study. Fertility and Sterility 2022.
616	30.	Hernáez Á, Wootton RE, Page CM, Skåra KH, Fraser A, Rogne T, Magnus P, Njølstad PR,
617		Andreassen OA, Burgess S <i>et al</i> : Smoking and infertility: multivariable regression and
618		Mendelian randomization analyses in the Norwegian Mother, Father and Child Cohort
619		Study. Fertility and Sterility 2022.
620	31.	Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, Hartwig FP, Holmes
621		MV, Minelli C, Relton CL et al: Guidelines for performing Mendelian randomization
622		investigations. Wellcome Open Res 2019, 4:186.
623	32.	Madley-Dowd P, Rai D, Zammit S, Heron J: Simulations and directed acyclic graphs explained
624		why assortative mating biases the prenatal negative control design. J Clin Epidemiol 2020,
625		118 :9-17.

626 627	33.	Ardissino M, Slob EAW, Millar O, Reddy RK, Lazzari L, Patel KHK, Ryan D, Johnson MR, Gill D, Ng FS: Maternal Hypertension Increases Risk of Preeclampsia and Low Fetal Birthweight:
628 629		Genetic Evidence From a Mendelian Randomization Study. <i>Hypertension</i> 2022, 79 (3):588- 598.
630 631	34.	Honigberg MC, Truong B, Khan RR, Xiao B, Bhatta L, Vy HMT, Guerrero RF, Schuermans A, Selvaraj MS, Patel AP <i>et al</i> : Polygenic prediction of preeclampsia and gestational
632		hypertension. Nat Med 2023.
633	35.	Brosens I, Pijnenborg R, Vercruysse L, Romero R: The "Great Obstetrical Syndromes" are
634		associated with disorders of deep placentation. Am J Obstet Gynecol 2011, 204 (3):193-201.
635	36.	Page JM, Silver RM: Interventions to prevent stillbirth. Semin Fetal Neonatal Med 2017,
636		22 (3):135-145.
637	37.	Nobles CJ, Mendola P, Mumford SL, Naimi AI, Yeung EH, Kim K, Park H, Wilcox B, Silver RM,
638		Perkins NJ <i>et al</i> : Preconception Blood Pressure Levels and Reproductive Outcomes in a
639		Prospective Cohort of Women Attempting Pregnancy . <i>Hypertension</i> 2018, 71 (5):904-910.
640	38.	Black MH, Sacks DA, Xiang AH, Lawrence JM: The relative contribution of prepregnancy
641		overweight and obesity, gestational weight gain, and IADPSG-defined gestational diabetes
642		mellitus to fetal overgrowth. Diabetes Care 2013, 36 (1):56-62.
643	39.	Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, Wapner RJ, Varner MW,
644		Rouse DJ, Thorp JM, Jr. et al: A multicenter, randomized trial of treatment for mild
645		gestational diabetes. N Engl J Med 2009, 361(14):1339-1348.
646	40.	Persson M, Norman M, Hanson U: Obstetric and perinatal outcomes in type 1 diabetic
647		pregnancies: A large, population-based study. Diabetes Care 2009, 32(11):2005-2009.
648	41.	Pervjakova N, Moen GH, Borges MC, Ferreira T, Cook JP, Allard C, Beaumont RN, Canouil M,
649		Hatem G, Heiskala A et al: Multi-ancestry genome-wide association study of gestational
650		diabetes mellitus highlights genetic links with type 2 diabetes. Hum Mol Genet 2022.
651	42.	Parikh NI, Gonzalez JM, Anderson CAM, Judd SE, Rexrode KM, Hlatky MA, Gunderson EP,
652		Stuart JJ, Vaidya D: Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique
653		Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement
654		From the American Heart Association. Circulation 2021, 143(18):e902-e916.
655	43.	Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA,
656		Selvin E, Stampfer M et al: Diabetes mellitus, fasting blood glucose concentration, and risk
657		of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010,
658		375 (9733):2215-2222.
659	44.	Stene LC, Eidem I, Vangen S, Joner G, Irgens LM, Moe N: The validity of the diabetes mellitus
660		diagnosis in the Medical Birth Registry of Norway Norsk Epidemiologi 2009, 17(2).
661	45.	Kemp MW: Preterm birth, intrauterine infection, and fetal inflammation. Front Immunol
662		2014, 5 :574.
663	46.	Shah PS: Paternal factors and low birthweight, preterm, and small for gestational age
664		births: a systematic review. Am J Obstet Gynecol 2010, 202(2):103-123.
665	47.	Gomez-Lopez N, Galaz J, Miller D, Farias-Jofre M, Liu Z, Arenas-Hernandez M, Garcia-Flores V,
666		Shaffer Z, Greenberg JM, Theis KR et al: The immunobiology of preterm labor and birth:
667		intra-amniotic inflammation or breakdown of maternal-fetal homeostasis. Reproduction
668		2022, 164 (2):R11-r45.
669	48.	Lie RT, Wilcox AJ, Skjaerven R: Maternal and paternal influences on length of pregnancy.
670		Obstet Gynecol 2006, 107 (4):880-885.
671	49.	Nilsen RM, Vollset SE, Gjessing HK, Skjaerven R, Melve KK, Schreuder P, Alsaker ER, Haug K,
672		Daltveit AK, Magnus P: Self-selection and bias in a large prospective pregnancy cohort in
673		Norway. Paediatr Perinat Epidemiol 2009, 23(6):597-608.
674		

33

675 SUPPLEMENTAL TABLES

676

Supplemental Table 1. Genetic variants used in the calculation of the genetic risk 677

- score for coronary heart disease. 678
- 679

Chromosome	Position	Reference	Effect	Effect allele	Beta	Standard	<i>p</i> -value	Available	Available
		allele	allele	frequency		error		in MoBa	in HUNT
1	2252205	_	Т						Yes
1	3325912		A	0.1355	0.0514	0.0084	9.97E-10	Yes	Yes
1	38456106	G	A	0.4303	-0.0326	0.0052	4.13E-10	Yes	Yes
1	55505647	G	Т	0.0164	-0.2406	0.0247	1.86E-22	No	Yes
1	56966350	G	A	0.9062	0.096	0.0088	8.04E-28	Yes	Yes
1	109821511	G	Т	0.2343	-0.0999	0.0062	3.63E-58	Yes	Yes
1	115753482	G	Α	0.3668	-0.0337	0.0054	4.16E-10	Yes	Yes
1	151768048	G	Α	0.1892	-0.0487	0.0073	2.85E-11	Yes	Yes
1	154422067	С	Т	0.4338	0.0395	0.0051	6.69E-15	Yes	Yes
1	169094459	С	Т	0.4956	-0.0362	0.0052	3.14E-12	Yes	Yes
1	200646073	С	Т	0.4715	-0.0284	0.005	1.77E-08	Yes	Yes
1	201872264	С	Т	0.3012	0.0359	0.0056	1.10E-10	Yes	Yes
1	210468999	С	Т	0.1501	0.0444	0.008	2.58E-08	Yes	Yes
1	222829550	G	Α	0.6821	0.0699	0.0064	5.91E-28	Yes	Yes
2	19942473	G	Α	0.1095	0.0812	0.0098	1.06E-16	Yes	Yes
2	21286057	С	Т	0.1837	-0.0555	0.0066	5.74E-17	Yes	Yes
2	44073881	С	Т	0.3038	0.0492	0.0056	1.84E-18	Yes	Yes
2	45896437	С	Α	0.5251	0.0332	0.0058	7.64E-09	Yes	Yes
2	85763520	С	Т	0.465	0.0565	0.0057	1.81E-23	Yes	Yes
2	145801461	С	Т	0.5299	-0.0368	0.0051	5.41E-13	Yes	Yes
2	164957251	G	Α	0.8189	0.0482	0.0074	6.31E-11	Yes	Yes
2	203873743	G	А	0.1174	0.1054	0.0089	1.29E-32	Yes	Yes
2	216304384	С	Т	0.2722	0.0435	0.0059	1.58E-13	Yes	Yes
2	218683154	G	А	0.3895	0.037	0.0052	1.56E-12	Yes	Yes
2	238223955	G	А	0.3157	-0.0339	0.0061	2.64E-08	Yes	Yes
3	14926351	С	Т	0.4344	0.0379	0.0057	3.21E-11	Yes	Yes
3	46688562	G	А	0.4061	0.0295	0.0052	1.10E-08	Yes	Yes
3	48193515	С	Т	0.6693	0.0355	0.0054	3.48E-11	Yes	Yes
3	124450081	G	С	0.1284	0.0639	0.0083	1.45E-14	Yes	Yes
3	132257961	G	Т	0.1433	-0.0431	0.0073	3.00E-09	Yes	Yes
3	136069472	G	Т	0.7751	0.0489	0.0063	6.08E-15	Yes	Yes
3	138092889	С	Т	0.1625	0.0644	0.0076	2.40E-17	Yes	Yes
3	154057741	G	С	0.1649	-0.0642	0.0081	3.36E-15	Yes	Yes
3	156852592	G	С	0.6774	-0.0346	0.0061	1.40E-08	Yes	Yes
	1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 2252205 1 3325912 1 3325912 1 38456106 1 55505647 1 56966350 1 109821511 1 109821511 1 115753482 1 151768048 1 151768048 1 151422067 1 169094459 1 201872264 1 201872264 1 210468999 1 22829550 2 19942473 2 21286057 2 44073881 2 45896437 2 85763520 2 145801461 2 164957251 2 203873743 2 218683154 2 218683154 2 218683154 2 238223955 3 14926351 3 1324450081 3 1324	I 2252205 C 1 3325912 C 1 3325912 C 1 38456106 G 1 55505647 G 1 56966350 G 1 109821511 G 1 115753482 G 1 151768048 G 1 169094459 C 1 200646073 C 1 20187264 C 1 20187264 C 1 210468999 C 1 221826057 C 2 145801461 C 2 45896437 C 2 145801461 C 2 164957251 G 2	Image Image <thimage< th=""> <thi< td=""><td>allele allele frequency 1 2252205 C T 0.1483 1 3325912 C A 0.1355 1 38456106 G A 0.4303 1 55505647 G T 0.0164 1 55505647 G A 0.9062 1 109821511 G T 0.2343 1 115753482 G A 0.3668 1 151768048 G A 0.4338 1 154422067 C T 0.4338 1 169094459 C T 0.4338 1 200646073 C T 0.4338 1 200646073 C T 0.4715 1 201872264 C T 0.3012 1 210468999 C T 0.1895 2 1286057 C T 0.4821 2 1286057</td><td>allele allele frequency 1 2252205 C T 0.1483 0.0469 1 3325912 C A 0.1355 0.0514 1 3325912 C A 0.4303 -0.0326 1 55505647 G T 0.0164 -0.2406 1 55956350 G A 0.9062 0.0999 1 109821511 G T 0.2343 -0.0999 1 115753482 G A 0.3668 -0.0337 1 151768048 G A 0.1892 -0.0487 1 15422067 C T 0.4338 0.0395 1 16909459 C T 0.4715 -0.0284 1 201872264 C T 0.3012 0.0359 1 210468999 C T 0.1501 0.0444 1 222829550 G A 0.6821 0.0699</td><td>Image: state in the s</td><td>Image: style interval allele allele frequency error interval 1 2252205 C T 0.1483 0.0469 0.0082 1.33E-08 1 3325912 C A 0.1355 0.0514 0.0084 9.97E-10 1 38456106 G A 0.4303 -0.026 0.0082 4.13E-10 1 55505647 G T 0.0164 -0.2406 0.0027 1.86E-22 1 56966350 G A 0.9062 0.0084 8.04E-28 1 109821511 G T 0.2343 -0.099 0.0062 3.63E-58 1 115758482 G A 0.1892 -0.0437 0.073 2.85E-11 1 154422067 C T 0.4338 0.0322 0.0051 1.69E-15 1 169044693 C T 0.4376 -0.0324 0.0051 1.10E-10 1 20168607 C <</td><td>Image: Note of the system of the sy</td></thi<></thimage<>	allele allele frequency 1 2252205 C T 0.1483 1 3325912 C A 0.1355 1 38456106 G A 0.4303 1 55505647 G T 0.0164 1 55505647 G A 0.9062 1 109821511 G T 0.2343 1 115753482 G A 0.3668 1 151768048 G A 0.4338 1 154422067 C T 0.4338 1 169094459 C T 0.4338 1 200646073 C T 0.4338 1 200646073 C T 0.4715 1 201872264 C T 0.3012 1 210468999 C T 0.1895 2 1286057 C T 0.4821 2 1286057	allele allele frequency 1 2252205 C T 0.1483 0.0469 1 3325912 C A 0.1355 0.0514 1 3325912 C A 0.4303 -0.0326 1 55505647 G T 0.0164 -0.2406 1 55956350 G A 0.9062 0.0999 1 109821511 G T 0.2343 -0.0999 1 115753482 G A 0.3668 -0.0337 1 151768048 G A 0.1892 -0.0487 1 15422067 C T 0.4338 0.0395 1 16909459 C T 0.4715 -0.0284 1 201872264 C T 0.3012 0.0359 1 210468999 C T 0.1501 0.0444 1 222829550 G A 0.6821 0.0699	Image: state in the s	Image: style interval allele allele frequency error interval 1 2252205 C T 0.1483 0.0469 0.0082 1.33E-08 1 3325912 C A 0.1355 0.0514 0.0084 9.97E-10 1 38456106 G A 0.4303 -0.026 0.0082 4.13E-10 1 55505647 G T 0.0164 -0.2406 0.0027 1.86E-22 1 56966350 G A 0.9062 0.0084 8.04E-28 1 109821511 G T 0.2343 -0.099 0.0062 3.63E-58 1 115758482 G A 0.1892 -0.0437 0.073 2.85E-11 1 154422067 C T 0.4338 0.0322 0.0051 1.69E-15 1 169044693 C T 0.4376 -0.0324 0.0051 1.10E-10 1 20168607 C <	Image: Note of the system of the sy

rs12897	3	172115902	G	A	0.5914	-0.0358	0.0059	1.21E-09	Yes	Yes
rs17081933	4	57822869	Т	Α	0.1979	0.0399	0.007	1.17E-08	Yes	Yes
rs12500824	4	77416627	G	Α	0.3565	0.0336	0.0053	1.64E-10	Yes	Yes
rs10857147	4	81181072	Т	А	0.7208	-0.0491	0.0064	1.37E-14	Yes	Yes
rs11099493	4	82587050	G	Α	0.6924	0.039	0.0062	2.49E-10	Yes	Yes
rs3775058	4	96117371	Т	Α	0.2341	0.0386	0.0067	7.63E-09	Yes	Yes
rs7678555	4	120909501	С	Α	0.7166	-0.0486	0.0063	1.23E-14	Yes	Yes
rs6841581	4	148401190	G	А	0.1559	0.0751	0.0074	5.18E-24	Yes	Yes
rs7692387	4	156635309	G	Α	0.1892	-0.0643	0.0065	3.34E-23	Yes	Yes
rs7696431	4	169687725	G	Т	0.5098	0.0311	0.0056	3.09E-08	Yes	Yes
rs112941079	5	9546098	G	Α	0.8676	0.0615	0.0085	3.75E-13	Yes	Yes
rs3936511	5	55860781	G	Α	0.823	-0.0366	0.0067	3.74E-08	Yes	Yes
rs273909	5	131667353	G	Α	0.8754	-0.0488	0.0078	4.74E-10	No	Yes
rs246600	5	142516897	С	Т	0.4633	0.043	0.0051	6.53E-17	Yes	Yes
rs9349379	6	12903957	G	Α	0.5907	-0.1072	0.0058	2.72E-76	Yes	Yes
rs6909752	6	22612629	G	A	0.3545	0.0442	0.0059	5.71E-14	Yes	Yes
rs644045	6	31883957	G	Α	0.3528	-0.0413	0.0057	2.80E-13	Yes	No
rs2814944	6	34552797	G	Α	0.1554	0.0479	0.0072	2.15E-11	Yes	Yes
rs1334894	6	35615130	С	Т	0.0919	-0.0482	0.0088	4.84E-08	Yes	Yes
rs1321309	6	36638636	G	Α	0.4907	0.028	0.0051	3.48E-08	Yes	Yes
rs10947789	6	39174922	С	Т	0.7671	0.0413	0.006	7.63E-12	Yes	Yes
rs6905288	6	43758873	G	Α	0.5807	0.0386	0.0056	4.00E-12	Yes	Yes
rs71566846	6	57148171	С	Т	0.0662	0.0829	0.0114	3.24E-13	Yes	Yes
rs4613862	6	82612271	С	Α	0.5314	0.0319	0.0052	6.58E-10	Yes	Yes
rs1591805	6	126717064	G	A	0.4927	0.037	0.0058	1.17E-10	Yes	Yes
rs2327429	6	134209837	С	Т	0.695	0.0655	0.0056	3.56E-31	Yes	Yes
rs17080091	6	150997401	С	Т	0.0839	-0.0537	0.0092	6.09E-09	Yes	Yes
rs55730499	6	161005610	С	Т	0.0693	0.3122	0.0118	9.78E-154	Yes	Yes
rs10267593	7	1937261	G	A	0.2012	-0.036	0.0064	1.88E-08	Yes	Yes
rs7797644	7	6486067	С	Т	0.2321	-0.0386	0.0069	2.10E-08	Yes	Yes
rs11509880	7	12261911	G	A	0.3612	0.0327	0.0059	3.27E-08	Yes	Yes
rs2107595	7	19049388	G	A	0.1767	0.0752	0.0073	1.25E-24	Yes	Yes
rs2107732	7	45077978	G	A	0.0874	-0.0567	0.0103	3.64E-08	No	Yes
rs2189839	7	107230026	G	A	0.2899	0.0345	0.0063	4.53E-08	Yes	Yes
rs975722	7	117332914	G	A	0.595	-0.0283	0.0052	4.17E-08	Yes	Yes
rs11556924	7	129663496	С	Т	0.3624	-0.0548	0.0055	1.37E-23	Yes	Yes
rs10237377	7	139757136	G	Т	0.3608	-0.0338	0.0058	6.53E-09	Yes	Yes
rs3918226	7	150690176	С	Т	0.0732	0.1071	0.0115	1.35E-20	Yes	Yes
rs6997340	8	18286997	С	Т	0.3025	0.0331	0.0056	4.60E-09	Yes	Yes
rs17091891	8	19843171	С	Т	0.8709	0.0585	0.0078	5.15E-14	Yes	Yes
rs6984210	8	22033615	G	С	0.939	-0.0784	0.0115	1.04E-11	No	Yes
rs10093110	8	106565414	G	A	0.4167	-0.0319	0.0057	1.88E-08	Yes	Yes
rs6982502	8	126479362	С	Т	0.5298	-0.0498	0.0051	7.67E-23	Yes	Yes
rs4977574	9	22098574	G	A	0.519	-0.1788	0.0056	8.82E-223	Yes	Yes
rs944172	9	110517794	С	Т	0.7197	-0.0395	0.0057	3.59E-12	Yes	Yes

rs885150	9	124420173	С	Т	0.7304	-0.0355	0.0058	7.86E-10	Yes	Yes
rs2519093	9	136141870	С	Т	0.1841	0.0554	0.0072	2.03E-14	Yes	Yes
rs61848342	10	12303813	С	Т	0.6355	-0.0363	0.0059	6.38E-10	Yes	Yes
rs9337951	10	30317073	G	Α	0.3178	0.0543	0.0064	1.73E-17	No	Yes
rs1870634	10	44480811	G	Т	0.3511	-0.06	0.0059	3.50E-24	Yes	Yes
rs17680741	10	82251514	С	Т	0.7152	0.042	0.0062	1.72E-11	Yes	Yes
rs1412444	10	91002927	С	т	0.3527	0.0559	0.0059	2.43E-21	Yes	Yes
rs3740390	10	104638480	С	Т	0.1066	-0.0662	0.0084	4.67E-15	Yes	Yes
rs4918072	10	105693644	G	Α	0.2713	0.0386	0.0063	9.63E-10	Yes	Yes
rs4752700	10	124237612	G	Α	0.5508	-0.0332	0.0051	8.02E-11	Yes	Yes
rs11601507	11	5701074	С	Α	0.0739	0.0782	0.0108	5.61E-13	Yes	Yes
rs472109	11	9770318	G	С	0.5698	0.0391	0.0057	6.26E-12	Yes	Yes
rs7926712	11	13303085	G	Α	0.3101	-0.0351	0.0061	9.41E-09	Yes	Yes
rs7116641	11	43696917	G	Т	0.6877	-0.0314	0.0055	1.03E-08	Yes	Yes
rs12801636	11	65391317	G	Α	0.2364	-0.0403	0.006	2.29E-11	Yes	Yes
rs606452	11	75276178	С	Α	0.1707	-0.0466	0.0071	4.76E-11	Yes	Yes
rs4754698	11	100631908	G	С	0.5399	-0.0368	0.0056	6.79E-11	Yes	Yes
rs974819	11	103660567	С	Т	0.3082	0.0614	0.0055	1.12E-28	Yes	Yes
rs651821	11	116662579	С	т	0.901	-0.0692	0.0096	7.03E-13	Yes	Yes
rs11838267	12	7175872	С	Т	0.8679	0.0514	0.0083	6.15E-10	No	Yes
rs10841443	12	20220033	G	С	0.3409	-0.046	0.0061	2.86E-14	Yes	Yes
rs11170820	12	54513915	G	С	0.9292	-0.0832	0.0117	9.28E-13	Yes	Yes
rs11613352	12	57792580	С	т	0.235	-0.036	0.0062	4.92E-09	Yes	Yes
rs2681492	12	90013089	С	т	0.8141	-0.0558	0.0072	8.64E-15	Yes	Yes
rs11107903	12	95507971	G	Α	0.0768	-0.0747	0.0105	1.06E-12	Yes	Yes
rs7137828	12	111932800	С	Т	0.5535	-0.0643	0.006	3.72E-27	Yes	Yes
rs1169288	12	121416650	С	Α	0.6725	-0.049	0.0056	1.26E-18	Yes	Yes
rs11057830	12	125307053	G	Α	0.1465	0.0655	0.0075	1.91E-18	Yes	Yes
rs9319428	13	28973621	G	Α	0.3121	0.036	0.0055	5.36E-11	Yes	Yes
rs7998440	13	33125206	G	Α	0.3549	-0.0383	0.0059	1.19E-10	Yes	Yes
rs9515203	13	111049623	С	т	0.7392	0.0596	0.006	3.89E-23	No	Yes
rs1317507	13	113631780	С	Α	0.2608	0.0398	0.0058	8.21E-12	Yes	Yes
rs2145598	14	58794001	G	Α	0.5758	-0.0283	0.0052	4.26E-08	Yes	Yes
rs7145159	14	75583268	С	т	0.5234	-0.0319	0.0051	3.60E-10	Yes	Yes
rs112635299	14	94838142	G	т	0.0193	-0.1363	0.0222	8.44E-10	Yes	Yes
rs8003602	14	100148961	С	т	0.2681	-0.0539	0.0066	2.89E-16	Yes	Yes
rs6494488	15	65024204	G	Α	0.8117	0.0382	0.007	3.90E-08	Yes	Yes
rs72743461	15	67441750	С	Α	0.2211	-0.0576	0.0069	5.68E-17	Yes	Yes
rs7173743	15	79141784	С	Т	0.5542	0.0636	0.0051	5.48E-36	Yes	Yes
rs1807214	15	89565257	С	Α	0.8891	0.0639	0.0097	5.21E-11	Yes	Yes
rs17514846	15	91416550	С	Α	0.4605	0.0559	0.0052	9.86E-27	Yes	Yes
rs17581137	15	96146414	С	Α	0.754	0.0373	0.0065	1.21E-08	Yes	Yes
rs12149545	16	56993161	G	A	0.3035	-0.0374	0.0062	1.19E-09	Yes	Yes
rs1050362	16	72130815	С	Α	0.3755	0.0352	0.0053	2.92E-11	Yes	Yes
rs8046696	16	75442143	G	Т	0.4311	-0.0479	0.0058	1.91E-16	Yes	Yes

medRxiv preprint doi: https://doi.org/10.1101/2023.08.18.23294257; this version posted August 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

0.3982

0.7594

0.2943

0.4379

0.5146

0.2197

0.1956

0.8632

0.3409

0.2122

0.4717

0.716

0.222

0.0202

0.8868

0.2162

0.4954

0.079

0.8971

0.2467

0.1437

0.1309

0.8258

0.1239

0.0367

0.0557

-0.0469

-0.032

-0.0358

0.0393

0.0423

-0.0469

0.048

0.0443

-0.033

-0.0382

0.0383

-0.1402

0.1157

0.0511

-0.0484

-0.1368

0.0573

0.0372

0.0424

0.0518

-0.0393

0.1083

0.0051

0.0068

0.0056

0.0052

0.0057

0.0069

0.0073

0.0076

0.006

0.0072

0.005

0.0063

0.0068

0.0224

0.0092

0.0069

0.0057

0.011

0.0084

0.0065

0.0072

0.0084

0.0067

0.009

9.36E-13

1.61E-16

4.11E-17

9.51E-10

2.90E-10

1.19E-08

7.36E-09

8.20E-10

1.63E-15

8.51E-10

6.28E-11

1.14E-09

2.02E-08

3.57E-10

1.93E-36

1.44E-13

2.36E-17

2.14E-35

6.84E-12

1.12E-08

4.40E-09

7.96E-10

4.16E-09

2.58E-33

Yes

G

G

С

G

С

С

G

С

G

С

С

С

С

G

С

G

С

С

G

G

С

С

G

G

Α

А

Т

А

Т

Т

С

Т

т

А

Т

А

Т

А

А

Т

А

Т

А

Α

Т

Т

А

А

81906423

83045790

2170216

17543722

27938424

30033514

40270238

45013271

47404628

59237013

62401965

47229717

57846077

8429323

11188153

17844942

41851509

45412079

33764554

39924279

44586023

57714025

30533076

35593827

rs7199941

rs7500448

rs170041

rs12936587

rs11080107

rs76954792

rs2074164

rs17608766

rs62076439

rs1476098

rs9892152

rs9964304

rs663640

rs116843064

rs55791371

rs7251815

rs4803455

rs867186

rs6102343

rs3827066

rs260020

rs2832227

rs28451064

680

rs7412

16

16

17

17

17

17

17

17

17

17

17

18

18

19

19

19

19

19

20

20

20

20

21

21

36

Yes

Yes

Yes

Yes

Yes

Yes

Yes

No

Yes

Supplemental Table 2. Sample sizes.

		Wome	en		Male par	artners		
	Main	Only stable	Both parents with	Main	Only stable	Both parents with		
	analyses	couples	genotype data	analyses	couples	genotype data		
Miscarriage	75,210	65,590	45,273	51,156	45,239	45,212		
Stillbirth	83,900	74,009	51,396	55,790	49,794	49,846		
Hypertensive disorders of pregnancy	83,114	73,339	50,906	55,273	49,341	49,377		
Pre-eclampsia + eclampsia	83,114	73,339	50,906	55,273	49,341	49,377		
Gestational diabetes	83,900	74,009	51,396	55,790	49,794	49,846		
Small for gestational age	66,110	58,857	40,703	43,967	39,395	39,334		
Large for gestational age	69,789	61,994	42,972	46,104	41,324	41,293		
Spontaneous preterm birth	83,522	73,640	51,167	55,536	49,595	49,621		

Supplemental Table 3. Description of participants with and without genotype data in MoBa and HUNT.

		Мо	Ва		HUNT				
	Wo	men	М	en	Wo	men	Men		
	Included	Non-included	Included	Non-included	Included	Non-included	Included	Non-included	
Birth year,	1975	1975	1973	1973	1964	1976	1962	1974	
median (1 st -3 rd quartile)	(1972-1979)	(1972-1979)	(1970-1977)	(1969-1976)	(1958-1971)	(1966-1985)	(1956-1969)	(1964-1983)	
Number of pregnancies,	2	2	2	2	2	2	2	2	
median (1 st -3 rd quartile)	(2-3)	(2-3)	(2-3)	(2-3)	(2-3)	(2-3)	(2-3)	(2-3)	
Participants in pregnancies									
with more than one different	9,147	2,099	5,819	2,945	745	203	178	51	
partner, <i>n</i> (%)	(13.3%)	(13.1%)	(12.3%)	(13.9%)	(4.74%)	(3.53%)	(2.08%)	(1.70%)	
Age in first pregnancy,	27	27	29	29	24	24	26	27	
median (1 st -3 rd quartile)	(24-30)	(24-30)	(26-33)	(26-33)	(20-27)	(21-28)	(23-29)	(24-30)	
Education years, mean ± SD	17.0 ± 3.36	16.7 ± 3.55	16.3 ± 3.56	16.0 ± 3.66	14.3 ± 4.13	15.0 ± 4.14	13.5 ± 4.08	14.1 ± 4.27	
Body mass index (kg/m ²),	23.1	23.0	25.4	25.4	25.2	25.3	26.6	26.7	

median (1 st -3 rd quartile)	(21.1-25.9)	(20.9-25.7)	(23.6-27.7)	(23.6-27.7)	(22.7-28.6)	(22.6-29.0)	(24.5-29.1)	(24.5-29.4)
Ever smokers, <i>n</i> (%)	35,632	8,071	24,294	11,461	8,865	3,080	4,233	1,533
	(52.3%)	(51.1%)	(51.2%)	(54.1%)	(57.0%)	(54.0%)	(50.1%)	(51.4%)
Total number of deliveries,								
mean ± SD	2.54 ± 0.85	2.55 ± 0.89	2.51 ± 0.81	2.54 ± 0.86	1.48 ± 0.88	1.28 ± 0.94	1.50 ± 0.81	1.31 ± 0.85
Miscarriage, n (%)	20,866	4,835	14,451	6,484	1,950	1,184	1,145	662
	(30.4%)	(30.7%)	(30.6%)	(31.0%)	(30.0%) ^a	(29.4%) ^a	(29.6%) ^a	(29.3%) ^a
Stillbirth, <i>n</i> (%)	872	238	581	313	198	45	84	19
	(1.27%)	(1.51%)	(1.23%)	(1.49%)	(1.30%)	(0.84%)	(0.99%)	(0.64%)
Any hypertensive disorders	7,288	1,730	5,186	2,297	1,500	483	870	288
of pregnancy, <i>n</i> (%)	(10.6%)	(11.0%)	(11.0%)	(11.0%)	(9.87%)	(9.02%)	(10.2%)	(9.66%)
Pre-eclampsia + eclampsia,	5,143	1,198	3,589	1,606	1,080	336	641	205
n (%)	(7.49%)	(7.61%)	(7.59%)	(7.67%)	(7.11%)	(6.28%)	(7.54%)	(6.88%)
Gestational diabetes, n (%)	1,495	474	1,041	553	127	111	62	69
	(2.18%)	(3.01%)	(2.20%)	(2.64%)	(0.84%)	(2.07%)	(0.73%)	(2.31%)
Small for gestational age,	10,552	2,706	7,354	3,608	1,544	251	862	136

(15.8%)	(17.7%)	(16.0%)	(17.8%)	(10.2%)	(4.69%)	(10.1%)	(4.56%)
14,620	3,063	9,880	4,375	1,733	285	1,070	179
(21.7%)	(20.0%)	(21.3%)	(21.4%)	(11.4%)	(5.33%)	(12.6%)	(6.00%)
6,282	1,508	4,187	2,027	2,643	688	1,509	385
(9.18%)	(9.63%)	(8.89%)	(9.73%)	(17.5%)	(13.0%)	(17.8%)	(13.0%)
_	14,620 (21.7%) 6,282	14,620 3,063 (21.7%) (20.0%) 6,282 1,508	14,620 3,063 9,880 (21.7%) (20.0%) (21.3%) 6,282 1,508 4,187	14,620 3,063 9,880 4,375 (21.7%) (20.0%) (21.3%) (21.4%) 6,282 1,508 4,187 2,027	14,620 3,063 9,880 4,375 1,733 (21.7%) (20.0%) (21.3%) (21.4%) (11.4%) 6,282 1,508 4,187 2,027 2,643	14,620 3,063 9,880 4,375 1,733 285 (21.7%) (20.0%) (21.3%) (21.4%) (11.4%) (5.33%) 6,282 1,508 4,187 2,027 2,643 688	14,620 3,063 9,880 4,375 1,733 285 1,070 (21.7%) (20.0%) (21.3%) (21.4%) (11.4%) (5.33%) (12.6%) 6,282 1,508 4,187 2,027 2,643 688 1,509

686 ^a: analyses restricted to 1998 or later pregnancies.


41

All rights reserved. No reuse allowed without permi

687 SUPPLEMENTAL FIGURES

688

- 689 Supplemental Figure 1. Associations between 1 SD increase in the genetic risk
- score for coronary heart disease and pregnancy outcomes in women (A) and men (B)
- 691 in MoBa and HUNT participants individually.



692 Analyses are adjusted for the first 20 ancestry-informative genetic principal

693 components and genotype batch.